Myriad Genetics Stock Performance
| MYGN Stock | USD 7.60 0.31 3.92% |
On a scale of 0 to 100, Myriad Genetics holds a performance score of 4. The company secures a Beta (Market Risk) of 2.02, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Myriad Genetics will likely underperform. Please check Myriad Genetics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Myriad Genetics' current price movements will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Myriad Genetics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile technical and fundamental indicators, Myriad Genetics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.92) | Five Day Return 9.99 | Year To Date Return (43.70) | Ten Year Return (82.53) | All Time Return 41.26 |
Last Split Factor 2:1 | Last Split Date 2009-03-26 |
1 | Disposition of 958 shares by Margaret Ancona of Myriad Genetics at 7.77 subject to Rule 16b-3 | 09/19/2025 |
2 | Myriad Genetics Shares Down 5.2 percent - Should You Sell - MarketBeat | 09/29/2025 |
3 | Insider Trading | 10/24/2025 |
4 | Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025 | 10/27/2025 |
5 | Why Myriad Genetics Stock Is Down Today | 11/04/2025 |
6 | Myriad Genetics, Inc. Q3 2025 Earnings Call Transcript | 11/05/2025 |
7 | Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference | 11/06/2025 |
8 | Acquisition by Dreismann Heinrich of 49796 shares of Myriad Genetics subject to Rule 16b-3 | 11/07/2025 |
9 | The Top 5 Analyst Questions From Myriad Geneticss Q3 Earnings Call | 11/10/2025 |
10 | Why The Story Around Myriad Genetics Is Evolving After Recent Analyst and Market Updates | 11/12/2025 |
11 | Prediction Market Myriad Partners With Walrus Decentralized Data Storage Layer | 11/18/2025 |
12 | Q3 Earnings Roundup Myriad Genetics And The Rest Of The Therapeutics Segment | 11/19/2025 |
13 | Prediction Market Myriad Hits 100M Milestone, Growing 10x in Three Months | 11/24/2025 |
14 | The Home Equity Partners Announces Strategic Investment from The Myriad Group | 11/26/2025 |
| Begin Period Cash Flow | 140.9 M | |
| Total Cashflows From Investing Activities | -11.9 M |
Myriad Genetics Relative Risk vs. Return Landscape
If you would invest 690.00 in Myriad Genetics on August 30, 2025 and sell it today you would earn a total of 70.00 from holding Myriad Genetics or generate 10.14% return on investment over 90 days. Myriad Genetics is currently generating 0.2497% in daily expected returns and assumes 4.3099% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Myriad, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Myriad Genetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Myriad Genetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Myriad Genetics, and traders can use it to determine the average amount a Myriad Genetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0579
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MYGN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.31 actual daily | 38 62% of assets are more volatile |
Expected Return
| 0.25 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Myriad Genetics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Myriad Genetics by adding it to a well-diversified portfolio.
Myriad Genetics Fundamentals Growth
Myriad Stock prices reflect investors' perceptions of the future prospects and financial health of Myriad Genetics, and Myriad Genetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Myriad Stock performance.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.0567 | ||||
| Profit Margin | (0.49) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 775.32 M | ||||
| Shares Outstanding | 93.21 M | ||||
| Price To Earning | 31.95 X | ||||
| Price To Book | 1.90 X | ||||
| Price To Sales | 0.86 X | ||||
| Revenue | 837.6 M | ||||
| Gross Profit | 580.7 M | ||||
| EBITDA | (59.5 M) | ||||
| Net Income | (127.3 M) | ||||
| Cash And Equivalents | 205.1 M | ||||
| Cash Per Share | 2.54 X | ||||
| Total Debt | 140.3 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.07 X | ||||
| Book Value Per Share | 4.00 X | ||||
| Cash Flow From Operations | (8.7 M) | ||||
| Earnings Per Share | (4.35) X | ||||
| Market Capitalization | 708.42 M | ||||
| Total Asset | 1.03 B | ||||
| Retained Earnings | (756.8 M) | ||||
| Working Capital | 133.9 M | ||||
| Current Asset | 314.5 M | ||||
| Current Liabilities | 72.3 M | ||||
About Myriad Genetics Performance
By examining Myriad Genetics' fundamental ratios, stakeholders can obtain critical insights into Myriad Genetics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Myriad Genetics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 39.80 | 41.79 | |
| Return On Tangible Assets | (0.27) | (0.25) | |
| Return On Capital Employed | (0.14) | (0.14) | |
| Return On Assets | (0.12) | (0.12) | |
| Return On Equity | (0.18) | (0.17) |
Things to note about Myriad Genetics performance evaluation
Checking the ongoing alerts about Myriad Genetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Myriad Genetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Myriad Genetics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 837.6 M. Net Loss for the year was (127.3 M) with profit before overhead, payroll, taxes, and interest of 580.7 M. | |
| Myriad Genetics currently holds about 205.1 M in cash with (8.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.54. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from australianmining.com.au: Saturn Metals deploys more drills after significant gold hits Apollo Hill |
- Analyzing Myriad Genetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Myriad Genetics' stock is overvalued or undervalued compared to its peers.
- Examining Myriad Genetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Myriad Genetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Myriad Genetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Myriad Genetics' stock. These opinions can provide insight into Myriad Genetics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.35) | Revenue Per Share | Quarterly Revenue Growth (0.04) | Return On Assets | Return On Equity |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.